These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 12208432)

  • 41. [Lipid profile in 4 minutes. Impressing your coronary heart disease patients].
    Janssen K
    MMW Fortschr Med; 2000 Jul; 142(26-27):39. PubMed ID: 10929482
    [No Abstract]   [Full Text] [Related]  

  • 42. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.
    Bersot TP; Pépin GM; Mahley RW
    Am Heart J; 2003 Dec; 146(6):1052-9. PubMed ID: 14660998
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Benefits of cardiac rehabilitation in the ninth decade of life in patients with coronary heart disease.
    Vonder Muhll I; Daub B; Black B; Warburton D; Haykowsky M
    Am J Cardiol; 2002 Sep; 90(6):645-8. PubMed ID: 12231096
    [No Abstract]   [Full Text] [Related]  

  • 45. Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess.
    Rosenson RS
    Arch Intern Med; 1996 Jun; 156(12):1278-84. PubMed ID: 8651835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety of anacetrapib in patients with or at high risk for coronary heart disease.
    Cannon CP; Shah S; Dansky HM; Davidson M; Brinton EA; Gotto AM; Stepanavage M; Liu SX; Gibbons P; Ashraf TB; Zafarino J; Mitchel Y; Barter P;
    N Engl J Med; 2010 Dec; 363(25):2406-15. PubMed ID: 21082868
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study.
    Frick MH; Manninen V; Huttunen JK; Heinonen OP; Tenkanen L; Mänttäri M
    Drugs; 1990; 40 Suppl 1():7-12. PubMed ID: 2289410
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Low concentrations of high-density lipoproteins (HDL) in plasma and coronary artery disease].
    Pérez-Méndez O; Luc G; Posadas-Romero C
    Arch Inst Cardiol Mex; 2000; 70(3):312-21. PubMed ID: 10959461
    [No Abstract]   [Full Text] [Related]  

  • 49. Diet and exercise in the regulation of plasma lipids and lipoproteins in patients at risk of coronary disease.
    Hartung GH
    Sports Med; 1984; 1(6):413-8. PubMed ID: 6390610
    [No Abstract]   [Full Text] [Related]  

  • 50. Lipoproteins as predictors of ischemic heart disease in non-insulin-dependent diabetic men.
    Barrett-Connor E; Philippi T; Khaw KT
    Am J Prev Med; 1987; 3(4):206-10. PubMed ID: 3452358
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Prevalence of cardiovascular risk factors in coronary heart disease patients with different low-density lipoprotein phenotypes].
    Slapikas R; Luksiene D; Slapikiene B; Babarskiene MR; Grybauskiene R; Linoniene L
    Medicina (Kaunas); 2005; 41(11):925-31. PubMed ID: 16333215
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is High Serum LDL/HDL Cholesterol Ratio an Emerging Risk Factor for Sudden Cardiac Death? Findings from the KIHD Study.
    Kunutsor SK; Zaccardi F; Karppi J; Kurl S; Laukkanen JA
    J Atheroscler Thromb; 2017 Jun; 24(6):600-608. PubMed ID: 27784848
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The evaluation of lipoprotein as a screening test for coronary heart disease].
    Li SC
    Zhonghua Liu Xing Bing Xue Za Zhi; 1989 Jun; 10(3):167-71. PubMed ID: 2776196
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Total cholesterol, low density lipoprotein cholesterol, and high density lipoprotein cholesterol and coronary heart disease in Scotland.
    Hargreaves AD; Logan RL; Thomson M; Elton RA; Oliver MF; Riemersma RA
    BMJ; 1991 Sep; 303(6804):678-81. PubMed ID: 1912914
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Indications for decreasing lipid values. Patients with healthy hearts with low HDL clearly profit].
    MMW Fortschr Med; 2000 Nov; 142(48):68. PubMed ID: 11138292
    [No Abstract]   [Full Text] [Related]  

  • 56. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
    Barter P; Gotto AM; LaRosa JC; Maroni J; Szarek M; Grundy SM; Kastelein JJ; Bittner V; Fruchart JC;
    N Engl J Med; 2007 Sep; 357(13):1301-10. PubMed ID: 17898099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Estrogen-receptor polymorphism and hormone-replacement therapy.
    Garrido JA
    N Engl J Med; 2002 Sep; 347(10):762-3; author reply 762-3. PubMed ID: 12213951
    [No Abstract]   [Full Text] [Related]  

  • 58. Triglyceride as a risk factor for coronary artery disease.
    Gotto AM
    Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Practice patterns related to the Adult Treatment Panel III guidelines in primary care.
    Eaton CB; Stamp MJ;
    Am J Cardiol; 2002 Sep; 90(6):687. PubMed ID: 12231113
    [No Abstract]   [Full Text] [Related]  

  • 60. Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers.
    Johnston N; Jernberg T; Lagerqvist B; Siegbahn A; Wallentin L
    Am J Cardiol; 2006 Mar; 97(5):640-5. PubMed ID: 16490429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.